Log in to your Inderes Free account to see all free content on this page.
Create account

Nanoform Finland

0.97 EUR

+28.67 %

3,738 following

NANOFH

First North Finland

Medical Equipment & Services

Health Care

+28.67 %
+75.45 %
+24.20 %
-17.66 %
-13.69 %
+1.58 %
-51.02 %
-83.84 %
-80.89 %

Nanoform Finland operates in the medical technology sector. The company specializes in research and development of nanoparticle technology used to create nanoparticles in pharmaceuticals. The technology is used as a complement in the production process and is used for the treatment of diseases such as ALS and Alzheimer's. Customers consist of players in the global pharmaceutical industry, with the largest operations in the Nordic market. Nanoform Finland is headquartered in Helsinki.

Read more
Market cap
82.67M EUR
Turnover
1.82M EUR
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
19.5.
2026

Interim report Q1'26

20.8.
2026

Interim report Q2'26

11.11.
2026

Interim report Q3'26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
Nanoform small is powerful Inside information: Nanoform Signs First Exclusivity Agreement for Ultra-High... Nanoform Finland Plc | Inside Information | May 12, 2026… “Sopimuksen mukaan kumppani maksaa Nanoformille palauttamattoman 1 000 000 Yhdysvaltain dollarin alkumaksun varmistaakseen...
yesterday
by Latupuikko
19
“This is our first exclusivity agreement for the biologics technology for a therapeutic target” → So, we are talking about a biologic, most likely a mAb (monoclonal antibody). This is why I am excited about the news; this is a preliminary external validation of the generalizability...
21 hours ago
by Clark kent
15
S.c. biologics has clearly been the most interesting part of the company, which jerej has explained to us many times. However, as an investment at this moment, Nanoform makes me wonder. Potential significant revenues are still further away even regarding this agreement; this will...
21 hours ago
by JusaVaan
12
Let me add that I was never incredibly excited about the benefits of nanoenzalutamide (was it that the tablet count was reduced from four to one or something like that?). However, this implies that it involves converting intravenous administration into a subcutaneous injection, which...
21 hours ago
by Clark kent
12
Ultra-high concentration subcutaneous receptor blocker Given that the press release did not mention Trastuzumab by name, and it has already been announced previously, I would guess this is another monoclonal antibody. The window for the commercial partnering of Nanotrastuzumab is...
21 hours ago
by jerej
11
The shareholder list has been updated on the website for April. Handelsbanken has stopped its selling, and the largest seller in the top 25 appears to have been Danske Invest, which has dropped off the list. Consequently, Danske must have sold at least -700k shares.
5/8/2026, 12:55 PM
by jerej
9
Halozyme recently acquired two companies producing these other hyper-concentrated biological compounds, Elektrofi for $900M and Surf Bio for $400M. Both of those are admittedly a bit further along in biological drug substances than Nanoform and are starting Phase 1 trials in the ...
16 hours ago
by jerej
6
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.